Skip to main content

Table 13 Incidence of treatment failures at each study visit (ITT)

From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients

Treatment

Total

Day 1

Day 3

Day 7

Day 14

N

N

%

N

%

N

%

N

%

Nepafenac group

106

2

1.9

2

1.9

2

1.9

2

1.9

Placebo group

105

0

0.0

1

1.0

9

8.6

9

8.6

P value

  

0.5467

 

0.3974

 

0.2001

 

0.2236

  1. NLMixed model P = 0.6151; main effect of treatment; failure defined as aqueous cells score ≥3 or aqueous flare score = 3 or ocular pain score ≥4